Amphotericin B is the mainstay of treatment in almost all systemic fungal infections, particularly those that affect the CNS. It destroys fungi primarily by binding to one or more sterols in their cytoplasmic membrane, thus altering membrane permeability. Almost all systemic mycoses respond to treatment with this drug, either alone or in combination with other drugs. The extent of response is dependent on the underlying health and immunocompetence of the patient, the organismresponsible, and the severity and extent of the infection
We analyzed the initial and overall responses to empiric therapy with amphotericin B as they related...
Systemic fungal infections are an important cause of morbidity and mortality among immunocompromised...
Multiple factors influence the outcome of fungal infection of the central nervous system (CNS). The ...
Amphotericin B acts through pore formation at the cell membrane after binding to ergosterol is an ac...
Amphotericin B, the first commercially significant antifungal drug, has been available for more than...
Fungal infections continue to be a major problem in the management of immunocompromised patients. De...
Systemic fungal infections represent a significant contributor to human morbidity and mortality. To...
"Amphotericin B acts through pore formation at the cell membrane after binding to ergosterol" is an ...
"Amphotericin B acts through pore formation at the cell membrane after binding to ergosterol" is an ...
Introduction: Amphotericin B (AmB) which belongs to the polyene group has a wide spectrum in vitro a...
Amphotericin B, one of the first systemic antifungal agents, has been in use since the past six deca...
Invasive fungal infections are associated with a poor outcome and their incidence is rising. Amphote...
The polyene macrolide amphotericin B (AmB) remains a critically vital antifungal as the last line of...
Invasive fungal infections are associated with a poor outcome and their incidence is rising. Amphote...
The administration of amphotericin B (AmB) is often limited by the development of nephrotoxicity. In...
We analyzed the initial and overall responses to empiric therapy with amphotericin B as they related...
Systemic fungal infections are an important cause of morbidity and mortality among immunocompromised...
Multiple factors influence the outcome of fungal infection of the central nervous system (CNS). The ...
Amphotericin B acts through pore formation at the cell membrane after binding to ergosterol is an ac...
Amphotericin B, the first commercially significant antifungal drug, has been available for more than...
Fungal infections continue to be a major problem in the management of immunocompromised patients. De...
Systemic fungal infections represent a significant contributor to human morbidity and mortality. To...
"Amphotericin B acts through pore formation at the cell membrane after binding to ergosterol" is an ...
"Amphotericin B acts through pore formation at the cell membrane after binding to ergosterol" is an ...
Introduction: Amphotericin B (AmB) which belongs to the polyene group has a wide spectrum in vitro a...
Amphotericin B, one of the first systemic antifungal agents, has been in use since the past six deca...
Invasive fungal infections are associated with a poor outcome and their incidence is rising. Amphote...
The polyene macrolide amphotericin B (AmB) remains a critically vital antifungal as the last line of...
Invasive fungal infections are associated with a poor outcome and their incidence is rising. Amphote...
The administration of amphotericin B (AmB) is often limited by the development of nephrotoxicity. In...
We analyzed the initial and overall responses to empiric therapy with amphotericin B as they related...
Systemic fungal infections are an important cause of morbidity and mortality among immunocompromised...
Multiple factors influence the outcome of fungal infection of the central nervous system (CNS). The ...